1. Generics Bulletin
  2. >>Products
  3. >>Value Added Medicines

Large Iranian Study Proves The Potential Of Polypill Concept

 
• By Aidan Fry

Data presented in The Lancet medical journal suggests a polypill fixed-dose combination of aspirin, atorvastatin and hydrochlorothiazide with either enalapril or valsartan could reduce the risk of cardiovascular events significantly. 

Iran_Map
Research conducted in the Golestan province of Iran supports the use of a polypill to reduce cardiovascular risk • Source: Shutterstock

A large-scale study in which more than 3,000 Iranians took ‘polypill’ tablets combining the blood-thinner aspirin, the cholesterol-lowering agent atorvastatin and the diuretic hydrochlorothiazide with either the enalapril or valsartan antihypertensives found that “use of a polypill was effective in preventing major cardiovascular events.”

Presenting their findings in TheLancet medical journal, researchers from the Tehran University of Medical Sciences and the University of Birmingham said that between February 2011 and April 2013 they enrolled...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

Fresenius Adds To Denosumab Competitors In Europe

 
• By Dave Wallace

At a busy meeting of the CHMP, the EMA issued positive opinions for Fresenius Kabi’s denosumab rivals to Prolia and Xgeva, another denosumab biosimilar from Sandoz, a Tecfidera hybrid from Neuraxpharm and a Descovy generic from Viatris. Meanwhile, Ascend has withdrawn a teriparatide filing.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

More from Products

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By Dean Rudge

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

 
• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.